Korro Bio, Inc.
No enriched coverage for $KRRO in the last 7 days.
Korro Bio (KRRO) director Jean Francois Formela reported indirect sales of 28,468 shares of common stock on August 19, 2026, by associated venture funds. The sales, totaling $399K, were made under a Rule 10b5-1 trading plan at a weighted average price of $14.00 per share. Formela disclaims beneficial ownership except for any pecuniary interest.
Lynx1 Capital Management LP purchased 6,684 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $11.79 ($11.40–$13.19) across 2 trades over 2026-08-06 to 2026-08-10.
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan
Recent KRRO coverage spans insider activity, corporate actions and financial news.
In the last 30 days, KRRO insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($502K). The most active reporter was FORMELA JEAN FRANCOIS with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sell represents a modest $399K divestment, likely exerting slight downward pressure on KRRO.
This is a modest insider-adjacent signal (10% owner, indirect) but not a fundamental catalyst like earnings or guidance.
Near-term catalyst is regulatory progress to start KRRO-121 clinical trials in 2H26, supported by EMA orphan designation and added pipeline (KRRO-111).
This is a routine equity-inducement grant with disclosed strike prices and vesting terms, implying modest dilution/overhang but no fundamental reset.
This is an insider sale disclosure; it may modestly affect sentiment but does not change fundamentals by itself.
AlphAI scores every news story that mentions KRRO with an AI model for sentiment and relevance, and aggregates insider trades from Korro Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Korro Bio (KRRO) director Jean Francois Formela reported indirect sales of 28,468 shares of common stock on August 19, 2026, by associated venture funds. The sales, totaling $399K, were made under a Rule 10b5-1 trading plan at a weighted average price of $14.00 per share. Formela disclaims beneficial ownership except for any pecuniary interest.
1 min readLynx1 Capital Management LP purchased 6,684 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $11.79 ($11.40–$13.19) across 2 trades over 2026-08-06 to 2026-08-10.
2 min readKorro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan
6 min readKorro Bio (Nasdaq: KRRO) said it granted non-statutory stock options to seven newly hired employees under its 2026 Inducement Plan. Four employees received options for 6,000 shares total at $10.59 per share (June 10, 2026 close), and three received options for 17,000 shares total at $14.72 (July 8, 2026 close). Options vest over four years.
2 min readFORMELA JEAN FRANCOIS sold 110,023 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.02 ($13.96–$14.03, $1.54M total) across 4 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.
2 min readFORMELA JEAN FRANCOIS sold 171,405 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.34 ($13.95–$14.98, $2.46M total) across 8 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.
2 min readKorro Bio, Inc. (KRRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001703647 NASDAQ 0001703647 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event report ed): J
2 min readAiyar Ram (President and CEO) sold 15,152 shares of Korro Bio, Inc. (KRRO) at $12.98 ($0.20M total) on 2026-05-29.
2 min readFORMELA JEAN FRANCOIS sold 419 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.95 on 2026-05-28 under a Rule 10b5-1 trading plan.
1 min readFORMELA JEAN FRANCOIS sold 2,441 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.95 on 2026-05-28 under a Rule 10b5-1 trading plan.
2 min read
